Riskpilot← Back to searchSign inGet full accessNordic Bioproducts Group Oy
OYActiveY-tunnus 3006967-4Tietotie 2-BManufacture of other chemical products n.e.c. · NACE 2059Est. 2019— employeeswww.nordicbioproducts.fi
Revenue 2024
EUR 1,8M
+382% vs 2023
EBITDA margin
-240.2%
-64% vs 2023
Equity ratio
43.4%
Financial strength
Net profit 2024
EUR -5,6M
-73% vs 2023
| Revenue | EUR 1,8M | +382% |
| EBITDA | EUR -4,4M | -64% |
| Net profit | EUR -5,6M | -73% |
| Total assets | EUR 25,3M | +25% |
| Equity | EUR 11M | +17% |
| Employees | — | — |
Legal name
Nordic Bioproducts Group Oy
Y-tunnus number
3006967-4
Legal form
Osakeyhtiö
NACE code
2059 · Manufacture of other chemical products n.e.c.
Founded
17. kesäkuuta 2019
Share capital
EUR 2 500
Employees
—
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Hallituksen puheenjohtaja ja toimitusjohtaja kumpikin yksin ja hallituksen jäsenet kaksi yhdessä
Company purpose
Yhtiön toimialana on kemiallisten tuotteiden valmistus ja kiertotalous- ja biotuotteiden sekä tekniikoiden tuotekehitys, tutkimus- ja suunnittelupalvelut ja muu laillinen liiketoiminta.
Address
Tietotie 2-B
Phone
+358505059464
Email
finance@nordicbioproducts.fi
Website
www.nordicbioproducts.fi
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 93 | 509 | 659 | 383 | 1 846 |
| Staff expenses | −432 | −315 | −787 | −1 178 | −2 927 |
| EBITDA | −726 | −239 | −1 496 | −2 699 | −4 434 |
| Depreciation & amort. | −20 | −87 | −174 | −275 | −253 |
| EBIT | −746 | −326 | −1 670 | −2 974 | −4 687 |
| Net financials | −2 | −3 | −108 | −278 | −932 |
| Profit before tax | −749 | −330 | −1 778 | −3 252 | −5 619 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −749 | −330 | −1 778 | −3 252 | −5 619 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 119 | 1 476 | 6 844 | 20 273 | 25 299 |
| Equity | −246 | 422 | 4 661 | 9 412 | 10 990 |
| Long-term debt | 33 | 799 | 1 257 | 8 655 | 11 486 |
| Short-term debt | 332 | 255 | 927 | 2 206 | 2 822 |
| Total debt | 365 | 1 054 | 2 183 | 10 861 | 14 309 |
EBITDA margin
-240.2%
This company
15.8%
Market median
-1620% vs market
20202024
Equity ratio
43.4%
This company
38.2%
Market median
+14% vs market
20202024
Return on equity
-51.1%
This company
18.4%
Market median
-378% vs market
20202024
Net profit margin
-304.4%
This company
8.1%
Market median
-3858% vs market
20202024
Asset turnover
0.07×
This company
1.12×
Market median
-94% vs market
20202024
Debt / equity
1.30×
This company
0.62×
Market median
-110% vs market
20202024
- Annual report 2024Filed via PRH / YTJ · Period 2023-12-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2022-12-01 – 2023-11-30
- Annual report 2022Filed via PRH / YTJ · Period 2021-12-01 – 2022-11-30
- Annual report 2021Filed via PRH / YTJ · Period 2020-12-01 – 2021-11-30
- Annual report 2020Filed via PRH / YTJ · Period 2019-06-01 – 2020-11-30
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
OJ Chief Executive Officer | Chief Executive Officer | 2023 |
| Former (2) | ||
EA Audit | Audit | 2019 – 2023 |
MV Deputy Member | Deputy Member | 2019 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (6) | ||
| Board of Directors | 2026 | |
| Board of Directors | 2026 | |
| Board of Directors | 2025 | |
| Chairperson | 2026 | |
| Board of Directors | 2026 | |
| Board of Directors | 2024 | |
| Former (7) | ||
| Board of Directors | 2023 – 2025 | |
| Board of Directors | 2022 – 2024 | |
| Chairperson | 2022 – 2023 | |
| Board of Directors | 2022 – 2023 | |
| Board of Directors | 2023 – 2026 | |
| Board of Directors | 2022 – 2023 | |
| Board of Directors | 2019 – 2019 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Nordic Bioproducts Group Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Esa Antero Rusanen | Audit | 0 companies |
| Miikka Valtteri Vimpari | Deputy Member | 0 companies |
| Olli Jochen Kähkönen | Chief Executive Officer | 0 companies |
| Norihisa Matsumoto | Board of Directors | 0 companies |
| Tero Olavi Saarno | Board of Directors | 0 companies |
| Leif Erik Frilund | Board of Directors | 0 companies |
| Felipe Alcalde Arrau | Board of Directors | 0 companies |
| Markku Tapio Hämäläinen | Chairperson | 0 companies |
| Veijo Tapio Meriläinen | Board of Directors | 0 companies |
| Vicktor Vilhelm Wahlberg | Board of Directors | 0 companies |
| Marjatta Inkeri Rytömaa | Chairperson | 0 companies |
| Risto Tapani Innanen | Board of Directors | 0 companies |
| Petri Sebastian Nikkilä | Board of Directors | 0 companies |
| Markku Armas Karlsson | Board of Directors | 0 companies |
| Krista Emilia Moisio | Board of Directors | 0 companies |
| Olli Pekka Dahl | Board of Directors | 0 companies |